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Abstract
Irisin, secreted by skeletal muscle and possibly fat, is hypothesized to play an important role in modulating energy
expenditure, obesity and metabolism. Coffee consumption also increases energy expenditure and leads to positive
metabolic effects, but whether these effects are mediated by irisin remains unknown. The objective of this study was to
determine the association between baseline irisin levels and the metabolic profile in humans and to investigate whether
consumption of caffeinated coffee alters irisin levels. To this end, a secondary analysis was performed investigating irisin
levels at baseline and after eight weeks in 32 healthy, overweight coffee drinkers who were randomized to consumption of
5 cups per day of instant caffeinated coffee, decaffeinated coffee, or water. Spearman correlation and analysis of covariance
analyses were performed to identify possible associations. Irisin levels were positively correlated with waist circumference
(r=0.41, p=0.02), fat mass (r=0.44, p=0.01) and CRP (r=0.47, p=0.007). Though there was a trend towards increased
levels of irisin over time in the caffeinated coffee group (+1.8%) when compared to the placebo group (24%) this did not
reach statistical significance (p=0.75 for the trend). This first randomized trial failed to reveal any effects of coffee
consumption on irisin levels, but a larger trial, appropriately sized on the basis of data provided by this study, is needed to
conclusively investigate such a relationship.
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Introduction
Irisin is a novel myokine thought to play an important role in
energy expenditure by mediating the exercise-induced browning
of fat [1–3]. As the browning of adipose tissue is hypothesized to
improve insulin sensitivity and decrease weight gain, irisin has
become an attractive target for potential anti-obesity therapy [4].
Though higher irisin levels are associated with lower body weight
and improved glucose tolerance in mice, the role of irisin in
human metabolism remains unclear [1,5]. Thus far, three cross-
sectional studies in humans have demonstrated that irisin levels are
lower in patients with type II diabetes, suggesting irisin could play
a protective role in glucose homeostasis [4,6,7]. The association
between irisin and body mass index (BMI) is more controversial
with two studies showing a negative relationship [4,6] and three
others showing a positive association [7–9]. While some of this
discrepancy could be attributed to the different and better
validated assay used in the latter three studies, it is also possible
that irisin regulation is more complex than first suspected [10].
Having reported the latter relationship between BMI and irisin in
our prior study [8], we proposed that irisin could be secreted in an
effort to counteract insulin resistance in the obese but that once
metabolic disease occurs, irisin resistance develops, similar to
several known hormone resistance syndromes [11]. A recent paper
by Polyzos et al supports this hypothesis, noting that irisin appears
to exhibit a positive relationship with BMI in healthy subjects but
an inverse relationship in diseased states [12]. Irisin’s relationships
to other important hormones including leptin and adiponectin
have been inconsistent across studies as well but are potentially
mediated by an underlying association between irisin and obesity
[8,9]. Ultimately, associations between irisin and metabolic factors
need to be further clarified, not only via simple association studies
but also using models that adjust for potential confounders such as
obesity.
Coffee consumption increases energy expenditure and is
thought to decrease the incidence of diabetes [13–16]. One
proposed mechanism to explain this association is that coffee may
facilitate glucose uptake by skeletal muscle via increased translo-
cation of the GLUT4 transporter to the plasma membrane [17–
19]. Also, coffee consumption has been associated with increased
levels of adiponectin, a hormone thought to have insulin-
sensitizing properties [20–22]. Thus, there is some evidence that
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e94463caffeine increases energy expenditure and positively affects
metabolism potentially via interaction with the skeletal muscle
and whether irisin is a potential mediator in this process is as yet
unknown.
The purpose of this study is twofold: to identify associations
between irisin and markers of metabolism in humans and to
determine whether coffee consumption affects irisin levels. As
caffeine increases energy expenditure and irisin levels appear to
rise with increased energy expenditure, we hypothesize that irisin
levels will increase with coffee consumption. To this end, we have
performed a secondary analysis of the serum levels of irisin in
overweight coffee drinkers who were randomly assigned to
consumption of caffeinated coffee, decaffeinated coffee, or water
for eight weeks. This study aims to shed further light on the
possible mechanisms by which irisin and coffee consumption can
lead to improved health outcomes.
Materials and Methods
Subjects
Forty-one overweight (BMI 25–35 kg/m
2) but otherwise
healthy adults who were regular coffee drinkers ($2 cups/day)
were recruited between 2006 and 2008 with inclusion and
exclusion criteria that have previously been described [20].
Participants were randomized via the PROC PLAN procedure
in the Statistical Analysis System 9.1 (SAS Institute Inc., NC, US)
to three different groups (caffeinated coffee, decaffeinated coffee,
no coffee) in block sizes of six. Thirty-two subjects were analyzed
in this study as the remaining samples were unavailable for assay
(Figure 1). The protocol for this trial and supporting CONSORT
checklist are available as supporting information (see Checklist S1
and Protocol S1).
Ethics Statement
This study was approved by the Beth Israel Deaconess Medical
Center (BIDMC) Committee on Clinical Investigations and
Institutional Review Board in accordance with the Helsinki
Declaration of 1975 as revised in 1983. All participants gave
written informed consent prior to participation in the study. The
clinical trial registration number is NCT00305097 at clinical-
trials.gov.
Protocol
After a two-week long caffeine washout and an overnight fast,
participants underwent baseline physical examination, blood draw
and oral glucose tolerance test (OGTT). Participants were
instructed to maintain their usual exercise and dietary habits
Figure 1. Flow of participants through the study.
doi:10.1371/journal.pone.0094463.g001
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study. Participants returned after eight weeks for adherence
questionnaires and repeat blood draws.
Intervention
Each day, participants in the two coffee arms of the study
consumed five two-gram portions of instant coffee (caffeinated or
decaffeinated Nestle ´’s Taster’s Choice) prepared with 6 ounces of
boiling water. Participants randomized to the no coffee arm drank
instead five 6-ounce glasses of water. As was previously reported,
the five daily cups of caffeinated coffee provided 345 mg caffeine
and 302 mg chlorogenic acid while five cups of decaffeinated
coffee provided 216 mg chlorogenic acid [20]. At six weeks, serum
caffeine levels were measured in all participants during a non-
fasting blood draw to assess for compliance [20].
Measurements
At each study visit, weight, height, and waist circumference
were measured by a trained investigator according to standard
definitions. Body composition was measured using Tanita (model
Quantum II, Lean Body software, RJL Systems,Clinton Town-
ship, MI, US) single frequency bioelectrical impedance analysis
[23,24]. Glucose was measured by glucose hexokinase method
using an autoanalyzer in the central clinical laboratory at the Beth
Israel Deaconess Medical Center. The homeostasis model
assessment for insulin resistance (HOMA-IR) was calculated as
[(fasting glucose 6fasting insulin)/405] from the OGTT [20]. All
samples were stored in a liquid nitrogen freezer at ,2130uC until
assayed. Samples were assayed in duplicate with all samples for the
same participant included in the same batch. The investigator
performing the assays was blinded to the intervention group that
the samples belonged in. Double-antibody radioimmunoassay
(Immulite Chemiluminescence, Siemens Co., New York, NY, US)
was used to measure insulin [intra-assay coefficient of variation
(CV) 2.1%], C-reactive protein (CRP) (CV 3.6%), and IL-6 (CV
4.7%). Adiponectin (CV 3.9%) and irisin (CV 6.3%) levels were
measured by enzyme linked immunosorbent assay kits (Millipore
Corporation, Billerica, MA, US, for adiponectin; Phoenix
Pharmaceuticals, Inc, Burlingame, CA, US, Cat. No. EK-067-53
for irisin) as previously described [8].
Statistical Analysis
Comparisons of the baseline characteristics for each group were
performed using x
2 test for categorical variables and analysis of
variance for the continuous variables with normal distribution (see
Figures S1–S5 to see scatter plots of the variables analyzed).
Normality test was done by Shapiro-Wilk test and Kruskal-Wallis
test was performed for non-normally distributed variables.
Spearman correlation coefficients were calculated to determine
associations between changes in irisin and the changes in the
biomarkers and anthropometric data (see Tables S1–S4 for
complete results).
For the interventional arm of this study, we conducted a
secondary analysis of the trial data, comparing the change in irisin
from baseline to the 8-week visit between the treatment groups
using an analysis of covariance model. The model included the
percentage change from baseline as the dependent variable with
adjustment for changes in fat mass and CRP over the eight week
period. Percentage change from baseline was calculated as the
difference between the eight week and baseline irisin levels divided
by the baseline level. The model was also examined with 8-week
irisin level as the dependent variable adjusted for the baseline irisin
level, change in fat mass and change in CRP. Statistical
significance was evaluated at an alpha level of 0.05 unless
otherwise indicated. All statistical analyses were performed using
SPSS Version 21 (SPSS, Inc., Armonk, NY). All data used in these
analyses can be made available on request.
Table 1. Baseline characteristics of subjects by coffee group.
Decaffeinated Coffee (n=10) Caffeinated Coffee (n=12) Placebo (n=10) p-value
Gender (% female) 3 (30) 5 (41.7) 5 (50) 0.70
Age (years) 40.3 (15.9) 36.7 (6.4) 48.3 (16.5) 0.14
Ethnicity (% non-Hispanic
white)
8 (80) 6 (50) 7 (70) 1.00
BMI 30.1 (1.9) 29.7 (2.0) 30.6 (1.8) 0.56
Irisin (ng/mL) 55.4 (8.0) 47.8 (5.5) 50.6 (8.7) 0.07
Hip circumference (cm) 110.2 (4.2) 106.1 (6.4) 108.7 (7.4) 0.29
Waist circumference (cm) 105.5 (6.4) 96.9 (8.1) 101.1 (8.3) 0.05
Fat mass (kg) 29.5 (6.3) 25.1 (6.5) 29.3 (6.0) 0.19
CRP (mg/L) 3.3 (1.4–12.7) 1.0 (0.33–1.4) 1.8 (0.91–6.4) 0.04
IL6 (pg/mL) 2.0 (1.0) 1.1 (0.6) 2.3 (1.4) 0.04
Adiponectin (mg/mL) 6.6 (3.9) 6.2 (2.7) 7.2 (2.6) 0.75
FPG (mg/dL) 85.9 (12.9) 87.5 (9.6) 82.3 (11.7) 0.64
HOMA-IR 2.7 (1.4–4.2) 2.0 (1.1–2.8) 2.1 (1.5–2.4) 0.05
Significant difference between groups at p,0.05.
Data displayed as means (standard deviation) for continuous variables and number (percentage) for categorical variables.
CRP and HOMA-IR are shown as median (interquartile range).
Abbreviations: BMI, body mass index; CRP, C-reactive protein; IL-6, interleukin 6; FPG, fasting plasma glucose;
HOMA-IR, the homeostasis model assessment for insulin resistance.
doi:10.1371/journal.pone.0094463.t001
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Baseline Characteristics
The average age (6SD) of these 32 subjects was 41.4 (613.8)
with a BMI of 30.1 (61.9). Other baseline characteristics of the
study population are shown in Table 1. The three groups were not
significantly different from each other aside from lower baseline
CRP and IL-6 levels in the caffeinated coffee group. Of note,
though age and gender distribution were similar in the 32 included
and 9 excluded samples, the average BMI of the subjects analyzed
was higher than that of the excluded samples (31.1 vs 27.9, p,
0.001).
Correlation between Irisin Levels and Anthropometric
Data
Correlations between irisin levels and baseline anthropometric
data are shown in Table 2a. Baseline irisin levels were positively
and significantly correlated with waist circumference (r=0.41,
p=0.02) and fat mass (r=0.44, p=0.01) and this relationship
remained even after adjustment for age and sex (r=0.38, p=0.04
for waist circumference and r=0.43, p=0.03 for fat mass, see
table S1). Though there was a positive association between irisin
and BMI (r=0.25, p=0.17), this did not reach significance.
Correlation between Irisin Levels and Other Biomarkers
of Metabolism
Correlations between irisin levels and changes in other
biomarkers over the study period are shown in Table 2b. Change
in irisin positively correlated with change in CRP (r=0.47,
p=0.007) though this was lost after adjustment for age, sex, and
BMI (r=0.31, p=0.1, see table S4). Though these did not reach
significance, irisin exhibited a direct relationship with change in
IL6 (r=0.29, p=0.1) and a negative relationship with change in
adiponectin (r=–0.12, p=0.53) in the unadjusted model.
Effect of Coffee Consumption on Irisin Levels
Results of the ANCOVA model calculating percentage change
in irisin levels over eight weeks by coffee group are graphically
depicted in Figure 2. Over eight weeks, irisin levels decreased by
5.5% in the decaffeinated coffee group (95% confidence interval of
220.1 to 9.1) and by 4% in the control group (–18.7 to 10.7) while
levels increased by 1.8% in the caffeinated coffee group (–11.9 to
15.5). Though irisin levels appeared to increase with caffeinated
coffee consumption, this did not reach statistical significance
(p=0.75). The ANCOVA model using eight-week irisin level as
the dependent variable with changes in CRP and fat mass as
covariates also found no significant differences between the three
groups (p=0.83).
Discussion
In this study, irisin levels demonstrated positive correlations with
markers of adiposity such as fat mass and waist circumference and
CRP, a marker of inflammation. While we had hypothesized that
irisin levels would rise with increased caffeine consumption, this
did not reach statistical significance.
The positive associations between irisin and markers of obesity
in this study support the findings of several recent studies and are
consistent with our prior hypothesis that irisin levels are increased
in obesity as a means of counteracting rising insulin resistance
[5,8,9,11,25]. A recent study found that irisin is secreted by
adipose tissue in addition to skeletal muscle providing a
mechanism that could explain the association between rising
BMI and irisin levels [26]. In further support of this theory, though
these associations failed to reach significance likely due to our
Figure 2. Percentage change in irisin levels over eight weeks by coffee group. Adjusted mean percent change estimates were determined
from analysis of covariance models with treatment group as a main effect and changes in fat mass and CRP as covariates. 95% confidence intervals
are graphically depicted.
doi:10.1371/journal.pone.0094463.g002
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markers of inflammation and HOMA-IR and inversely related to
the insulin-sensitizing hormone adiponectin. These findings add to
the small but growing body of literature which suggests that irisin
is associated with obesity-linked insulin resistance in humans. This
continues to be an active area of research and more studies in
humans are necessary to better understand the complex role of
irisin in human metabolism.
Coffee intake increases energy expenditure and has been
associated with a decreased incidence of diabetes and the
metabolic syndrome in multiple studies [15,16,20–22]. The
mechanism of this effect is not yet clear but could be a result of
improved glucose uptake by skeletal muscle or up-regulation of
insulin sensitizing hormones such as adiponectin [17,20]. Though
irisin is secreted in response to exercise, another state of increased
energy expenditure, we did not detect a statistically significant
change in irisin levels after eight weeks of coffee consumption [8].
Using these initial data, power calculations were performed using
GPower 3.1.6 (Franz Faul, Universita ¨t Kiel, Germany) which
showed that 53 samples would be required in each group to
investigate this relationship, approximately five times the number
analyzed in this cohort. Prior to this study there was no data with
which to perform such a power analysis. Thus ultimately, a larger
scale clinical trial would be needed to conclusively demonstrate
whether the trend towards increased irisin levels in those who
consume caffeine is indeed significant.
The key limitation of this study is the small and fixed sample
size, limiting the power of the study to identify significant
relationships and increasing the likelihood of extreme values
affecting the results; however, prior to this study no data were
available to determine the appropriate sample size. In terms of
anthropometric data, the association between irisin and BMI
might have been attenuated by the small range of BMI in this
study given that all participants were overweight at baseline. The
small size and relative homogeneity of this study population also
limits generalizability of our findings.
Strengths of the study include that it is the first randomized
controlled trial that has investigated the effects of coffee intake on
irisin levels. We found positive associations between irisin and
several markers of obesity, lending credence to the hypothesis that
irisin may be secreted by fat in addition to muscle in response to
obesity-linked insulin resistance. The data reported in this rather
small study can be used to perform power calculations for larger
clinical trials and mechanistic studies which are needed to more
firmly establish the role of irisin in metabolism and to better
understand its potential association with coffee.
Supporting Information
Figure S1 Scatter plot depicting irisin levels versus BMI
and waist circumference.
(TIF)
Figure S2 Scatter plot depicting irisin levels versus
waist: hip ratio and fat mass.
(TIF)
Figure S3 Scatter plot depicting irisin levels versus CRP
and adiponectin.
(TIF)
Figure S4 Scatter plot depicting irisin levels versus
fasting plasma glucose and HOMA-IR.
(TIF)
Figure S5 Scatter plot depicting irisin levels versus IL6.
(TIF)
Table S1 Spearman correlation coefficients between
irisin levels and baseline anthropometric data.
(TIF)
Table S2 Spearman correlation coefficients between
irisin levels and changes in anthropometric data.
(TIF)
Table S3 Spearman correlation coefficients between
irisin levels and baseline biomarker levels.
(TIF)
Table S4 Spearman correlation coefficients between
irisin levels and changes in biomarkers.
(TIF)
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Study Protocol.
(DOC)
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